BioAtla’s (BCAB) “Market Perform” Rating Reiterated at JMP Securities

JMP Securities reaffirmed their market perform rating on shares of BioAtla (NASDAQ:BCAB) in a report published on Wednesday,Benzinga reports.

A number of other equities analysts have also weighed in on the stock. Citizens Jmp lowered shares of BioAtla from an “outperform” rating to a “market perform” rating in a research report on Wednesday. Wall Street Zen raised shares of BioAtla from a “sell” rating to a “hold” rating in a research note on Friday, June 6th.

BioAtla Trading Up 1.0%

BCAB opened at $0.37 on Wednesday. The firm has a market capitalization of $21.59 million, a PE ratio of -0.33 and a beta of 0.90. BioAtla has a twelve month low of $0.24 and a twelve month high of $2.53. The firm’s 50-day moving average price is $0.38 and its 200 day moving average price is $0.39.

BioAtla (NASDAQ:BCAB) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.02). As a group, analysts predict that BioAtla will post -1.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioAtla

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Acorn Capital Advisors LLC raised its position in BioAtla by 19.9% in the second quarter. Acorn Capital Advisors LLC now owns 4,835,111 shares of the company’s stock valued at $1,915,000 after purchasing an additional 803,065 shares during the period. Acadian Asset Management LLC raised its position in BioAtla by 968.9% in the first quarter. Acadian Asset Management LLC now owns 1,690,110 shares of the company’s stock valued at $585,000 after purchasing an additional 1,531,994 shares during the period. Woodline Partners LP purchased a new stake in BioAtla in the first quarter valued at $26,000. Two Sigma Investments LP raised its position in BioAtla by 84.0% in the fourth quarter. Two Sigma Investments LP now owns 135,177 shares of the company’s stock valued at $80,000 after purchasing an additional 61,725 shares during the period. Finally, Tang Capital Management LLC raised its position in BioAtla by 57.2% in the fourth quarter. Tang Capital Management LLC now owns 1,374,076 shares of the company’s stock valued at $812,000 after purchasing an additional 500,000 shares during the period. Hedge funds and other institutional investors own 77.23% of the company’s stock.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.